Biotech News

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Company update

Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancer KAT6A degradation was active in both ESR1-mutant and wild-type cell models Degraders were well-tolerated in all groups SAN FRANCISCO, Nov.

Related news

OLMAOlema Pharmaceuticals, Inc.2026-11-04 21:01 EST

Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium

OLMAOlema Pharmaceuticals, Inc.2026-11-10 12:00 EST

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

RVMDRevolution Medicines2026-11-19 23:05 EST

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

BNTXBioNTech2026-10-26 09:00 EST

BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekannt

GSKGSK plc2026-10-18 19:36 EST

GSK presents first global data for Ris-Rez in extensive-stage small cell lung cancer

BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

Stock data

Close
7.15 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States